|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||
| Current Assets: | ||||||||||||||
| Prepaid expenses | ||||||||||||||
| Cash | ||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||
| Total Current Assets | ||||||||||||||
| Cash held in the Trust Account | ||||||||||||||
| Prepaid expenses – non-current | ||||||||||||||
| Total Assets | ||||||||||||||
| LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||
| Accrued offering costs | ||||||||||||||
| Convertible note - sponsor | ||||||||||||||
| Note payable | ||||||||||||||
| Extension loans – sponsor | ||||||||||||||
| Working capital note - sponsor | ||||||||||||||
| Total Current Liabilities | ||||||||||||||
| Deferred underwriting commission | ||||||||||||||
| Total Liabilities | ||||||||||||||
| Temporary equity carrying amount | ||||||||||||||
| Shareholders’ Deficit: | ||||||||||||||
| Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 2,346,143 shares issued and outstanding at March 31, 2025 and June 30, 2024 (excluding 818,795 and 1,337,763 shares subject to possible redemption at March 31, 2025 and June 30, 2024, respectively) | ||||||||||||||
| Accumulated deficit | ||||||||||||||
| Total Shareholders’ Deficit | ||||||||||||||
| Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit |
Loading...
